BODY
Evidence-based body & physical wellness editorial
Spain's Provital Targets the Hypodermis with Intensilk, a New Layer for Topical Skincare
Spanish ingredient maker Provital introduced Intensilk at in-cosmetics 2026 — an active that claims to target the hypodermis, the deepest skin layer. The pitch reframes GLP-1 sag and cellulite as one problem at the same depth.
4,300 Women, Nine Countries, Three Skin Changes At Once: Galderma's Menopause Survey
Galderma's global survey across 4,300 peri- and post-menopausal women shows 60% feel less attractive after menopause-related skin changes, and most discovered the impact only by experiencing it.
Menopausal Hormone Therapy Plus Tirzepatide Yields 35% More Weight Loss. Mayo Clinic Puts A Number On It
A Mayo Clinic cohort reports that menopausal women on hormone therapy plus tirzepatide (Zepbound) lost roughly 35% more weight than peers on the drug alone, published in The Lancet Obstetrics, Gynaecology and Women's Health 2026. It's the first clinical-scale quantification of the estrogen-GLP-1 synergy hypothesis. The authors flag the observational design as a clear limit.
Bromelain + Alpha-Lipoic Acid Cuts Edema and Seroma After Breast Conservative Surgery — Sci Rep RCT
A double-blind, placebo-controlled randomized trial from the BCU PoliBa group at the University of Bari (Scientific Reports 2025) followed 114 breast conservative surgery patients on a 30-day postoperative supplement protocol. Edema fell significantly at day 1 (P=0.018) and 1 month (P=0.002); seroma fell at 15 days (P=0.009) and 1 month (P<0.001) versus placebo. The first robust RCT validating supplement-based post-surgical recovery.
Tonmya FDA — First Fibromyalgia Drug in 15 Years. 10M US Patients 80% Women Blind Spot Released
Tonix Pharmaceuticals Tonmya (cyclobenzaprine sublingual) 2025.11 FDA approval. First fibromyalgia drug in 15 years. RELIEF/RESILIENT Phase 3 n=1,474. 14-week pain reduction -1.9 vs placebo -1.5 (p=0.01). Non-opioid bedtime. US fibromyalgia 10M patients 80% women = policy gap first resolution.
Saphnelo Pen FDA — Lupus SLE Self-Injection Era. 90% Female Patients, Hospital to Home
AstraZeneca Saphnelo (anifrolumab) 2026.4.27 FDA self-injection pen approval. Weekly 120mg subcutaneous. Monthly IV infusion → home self-administration transition. SLE 90% female patients. L64 Gazyva anti-CD20 + L73 Saphnelo Pen = autoimmune self-management era entry.
SARM MK-0773 Female Sarcopenia 6-Month RCT — Post-Menopausal Muscle via Drug. Hormone Target New Dimension
Journal of Cachexia, Sarcopenia and Muscle Phase IIa RCT. 65+ women n=170 6 months. Selective Androgen Receptor Modulator (SARM) MK-0773 muscle mass significant increase. FDA approved sarcopenia drugs = 0. Post-menopausal muscle recovery drug new dimension. Different from L69 UConn testosterone via SARM target.
Sibel ANNE Maternal FDA 510(k) — First Fully Wireless Maternal-Fetal Monitoring. US Maternal Mortality 22/100k Blind Spot
Sibel Health 2026.4.9 FDA 510(k) clearance. First fully wireless maternal-fetal integrated monitoring. US maternal mortality 22/100k (developed countries worst·2x+). 2026 Gates Foundation annual letter listing for India·Pakistan·Nigeria·Rwanda 4-country deployment. Era of mothers not bound to beds.
Elitone OTC FDA 510(k) — Pelvic Floor Self-Stimulation. Women's Incontinence 30~40% Blind Spot First OTC Release
Elidah Elitone FDA 510(k) 2026.3.31·general sale 2026.4. Non-invasive OTC neuromuscular stimulation pelvic floor device. Postpartum·post-menopausal women incontinence 30~40%·treatment rate <20%. Electrotherapy + photobiostimulation combo. Shame blind spot first OTC entry.
WHOOP 11 Women's Biomarkers + Hormonal Insights — FemTech's First Medical-Grade ECG·AMH Home Measurement
WHOOP 2026.3.10 launch. Women's health 11 blood markers (AMH·progesterone·prolactin·TPOAb·Free T4/T3·leptin·B12·folate·Mg·P) + AI hormonal symptom prediction. WHOOP MG ECG+BP integration. FemTech's first medical-grade ECG + ovarian reserve (AMH) home measurement era.
UConn STEP-HI — Testosterone Gel Blocks Visceral Fat in 65+ Women. Exercise Alone Can't
Obesity Pillars 2026. UConn STEP-HI trial — 66 women aged 65+ in hip fracture recovery, 6-month follow-up. Testosterone gel + exercise group: visceral fat decreased. Exercise alone group: visceral fat normally increased. First RCT evidence that postmenopausal visceral fat needs hormone axis + exercise integration. ScienceDaily 2026.5.7.
Eli Lilly's Retatrutide Phase 3 Hits 28.7% Weight Loss at 68 Weeks — Stronger Effect in Women
Eli Lilly's retatrutide (GLP-1 + GIP + glucagon triple agonist) achieved mean 28.7% weight loss in TRIUMPH-4 phase 3 at 12mg dose over 68 weeks. Women showed stronger response than men in Phase 2 (28.5% vs 19.8% at 8mg). Surpasses semaglutide (15-17%) and tirzepatide (20-22%) — a new era in obesity drugs. New side effect signal: dysesthesia 21%.
Veppanu (vepdegestrant) FDA Approval — First PROTAC Cancer Drug. ESR1-Mutated Breast Cancer PFS 5.0 Months
FDA approved vepdegestrant (Veppanu·Arvinas) on May 1, 2026 for ESR1-mutated ER+/HER2- advanced·metastatic breast cancer. First Proteolysis Targeting Chimera (PROTAC) class anticancer drug. VERITAC-2 trial PFS 5.0 months vs fulvestrant 2.1 months (43% risk reduction). 40~50% of patients post CDK4/6 + endocrine therapy progression have ESR1 mutations — broad target population.
Multi-Strain Probiotics Dysmenorrhea RCT — 36% Pain Score Reduction in 3 Months. First RCT-Grade Non-Hormonal Option
Scientific Reports 2026. 48-person randomized double-blind RCT. Multi-strain Lactobacillus·Bifidus probiotics for 3 months reduced NRS pain score from 5.8 → 3.7 (36% reduction vs placebo). Effect lost after discontinuation (sustained use needed). First RCT-grade non-hormonal option beyond hormonal contraceptives·NSAIDs. New ladder for primary dysmenorrhea affecting 50~90% of reproductive-age women.
GLP-1 Muscle Loss Concern Collapses — 36-Trial Meta-Analysis. 9% Weight Loss + Muscle Preservation Disarms 'Sagging Body' Fear
Nature International Journal of Obesity May 2026. 36 clinical trial meta-analysis showed GLP-1 users averaged 9% weight loss at 3 months + dominant visceral·body fat reduction at 12 months with modest lean mass loss. 'High quality weight loss' conclusion. Women's biggest fear about obesity drugs is academically dismantled.
Denosumab vs Alendronate Head-to-Head: 12-Month Postmenopausal BMD — Denosumab Wins Spine, Hip, and Forearm
Journal of Bone and Mineral Research 2024 + 2026 guideline updates. Denosumab 60mg every 6 months vs alendronate 70mg weekly for 12 months → denosumab significantly superior in spine, hip, and forearm BMD. No GI burden + 6-month subcutaneous injection convenience. But discontinuation rebound fracture risk → must transition to antiresorptive.
Romosozumab (Evenity) Builds Bone and Blocks Resorption Simultaneously in Postmenopausal Women — A Paradigm Shift Beyond Bisphosphonates
Amgen and UCB's romosozumab (Evenity) blocks sclerostin to stimulate osteoblast formation while simultaneously inhibiting resorption. The ARCH trial showed 48% vertebral fracture reduction vs alendronate. One year of monthly subcutaneous injections, then transition to antiresorptive. Becoming the first-line option for postmenopausal women at high fracture risk.
Oral Wegovy (Semaglutide 25mg Tablet) Wins FDA Approval. 16.6% Weight Loss at 64 Weeks Plus 20% Cardiovascular Event Reduction
Novo Nordisk's oral Wegovy received FDA approval in January 2026 — the first oral GLP-1 with both obesity and cardiovascular indications. OASIS 4 showed mean 16.6% weight loss at 64 weeks vs 2.7% placebo. SELECT trial in 17,604 patients showed 20% major adverse cardiovascular event reduction. A new first-line option for women avoiding injection. Korean market entry expected within 12~18 months.
DHEA Topical and Vaginal in Postmenopause — Prasterone (Intrarosa) as a New Option for Skin, Collagen, Vaginal Atrophy
DHEA addresses postmenopausal adrenal androgen decline through three routes: oral, topical (skin collagen), and vaginal suppository (Prasterone, FDA 2016 approved). Safe up to 50 mg daily; absolutely contraindicated in hormone-sensitive cancer. Monitor androgen side effects (acne, hirsutism).
Silymarin (Milk Thistle) Reduces Insulin Resistance in Non-Diabetic Obese Women — Beyond Liver Protection
A 2024 clinical study reported silymarin (milk thistle's active compound) reduced insulin resistance in non-diabetic obese women. Adds metabolic targeting beyond traditional liver protection. Standard dose: 140-210 mg × 2-3 daily for 8-12 weeks. Spring detox season's molecular coordinate.
Spirulina Recovers Hemoglobin and Ferritin in 18-21 Anemic Women — Plant Iron's Newer Possibility
Randomized double-blind comparative study of Spirulina platensis in anemic women aged 18-21 reported significant hemoglobin and ferritin increases vs placebo. Non-heme plant iron, but 28.5 mg per 100 g content + absence of phytate/oxalate/tannin → high absorption. New option for vegetarian women, ferritin recovery, and pregnancy.
TOSLA + Geltor PrimaColl Launches Type 21 Vegan Signaling Collagen — 170-Woman Trial Shows 80-92% Improvement
TOSLA and Geltor launched the first Type 21 vegan signaling collagen liquid supplement (PrimaColl) in April 2026, made via precision fermentation. A 170-woman 12-week RCT showed 80-92% improvement in firmness, elasticity, moisturization, and wrinkle depth at 1-2.5 g daily. New category alternative to animal and marine collagen.
Postpartum Telogen Effluvium: Why 6-12 Month Recovery Stalls Without Ferritin, Vitamin D, Zinc, Protein
30-50% of postpartum women develop telogen effluvium starting 3 months post-delivery, peaking at 4-6 months. Natural recovery in 6-12 months — but ferritin <30 ng/mL, vitamin D <50 nmol/L, and zinc deficits delay it. Protein 1.2 g/kg + ferritin + vitamin D + zinc 4-tier matrix.
SEMALEAN: Semaglutide 12 Months — Fat -18.9%, Lean Stable, Handgrip +4.1 kg, Sarcopenic Obesity 49→33% in Women-Majority Cohort
Semaglutide 2.4 mg weekly for 12 months in 106 obese adults (68.9% women). Weight -12.7%, fat mass -18.9%, lean mass -3 kg at 7 months then stable, handgrip +4.1 kg, sarcopenic obesity prevalence 49→33%. Women showed greater weight, fat, and lean changes than men.
Creatine 2-Year Trial: BMD Unchanged, but Femoral Bone Geometry Improved in Postmenopausal Women
A 237-participant 2-year RCT showed creatine plus resistance training did not change femoral BMD but improved proximal femur bone geometry. Another 2-year trial in osteopenic women showed no benefit, clarifying that resistance training co-administration is the decisive variable.
BMS Updates January 2026 Tool for Prescribing Testosterone in Menopausal Women
The British Menopause Society released an updated clinician's tool in January 2026 covering indications, dosing, and monitoring for female testosterone prescription. The primary indication is hypoactive sexual desire disorder (HSDD), with libido response in 6-12 weeks and energy in 4-8 weeks.
Ozempic Face: 63% of U.S. Med Spa Patients Added Aesthetic Procedures After GLP-1
Rapid weight loss from GLP-1 agonists drives facial fat compartment loss, infraorbital hollowing, and temporal concavity. A survey of 174 U.S. medical spas found that 63% of patients did not seek facial aesthetics before weight loss but added procedures afterward, with U.S. aesthetic patients spending $160 million per month on weight loss treatments.
DIM Reshapes Estrogen Metabolism in Postmenopausal Women on Estradiol Patches
A July 2025 Menopause Journal study tracking 1,458 postmenopausal women on transdermal estradiol patches found that those concurrently taking DIM showed elevated protective 2-OHE1 metabolites and reduced proliferative 16-OHE1, signaling a complementary strategy for widening the safety margin of hormone replacement therapy.
High-Molecular-Weight Oat Beta-Glucan Beverage Cuts LDL by 6% and CVD Risk by 8% in 4 Weeks
The same 3g dose produced different outcomes depending on molecular weight. A Journal of Nutrition trial shows why the structure of beta-glucan matters as much as the amount.
Lactoferrin 600mg Reawakens Immune Cells After Age 50
A 4-week randomized controlled trial published in the Proceedings of the Nutrition Society found that 600mg/day lactoferrin significantly increased T cell populations and reduced IL-6 and CRP in healthy adults aged 50 and over. The 200mg dose engaged different immune pathways entirely.
Kiwifruit Extract 8-Week Trial Cuts IBS-C Pain by 30 Percent
A 2025 double-blind RCT in JGH Open found that 575mg kiwifruit extract taken daily for eight weeks significantly improved spontaneous bowel movement frequency, stool consistency, and abdominal pain in IBS-C patients, with the strongest effects in those with severe baseline pain.
Spermidine Autophagy: 187 Elderly Heart Patients, Answers This August
Aarhus University Hospital is giving 187 coronary artery disease patients aged 65+ a daily 24mg dose of spermidine for 48 weeks. The POLYCAD trial wraps in August 2026, and it's the largest RCT yet to test whether autophagy can slow cardiovascular aging.
DHM Supplement 12 Months, Liver Enzyme Normalization 7x Placebo
A 12-month randomized controlled trial in MASLD patients found combined ALT/GGT normalization in 35% of the DHM group versus 5% placebo — a 7-fold difference. The hovenia dulcis-derived compound also improved blood glucose, cholesterol, and liver stiffness.
12 Weeks of Beetroot Nitrate Reverses Postmenopausal Carotid Stiffness
A randomized double-blind trial in 60–85-year-old postmenopausal women found that 12 weeks of dietary nitrate supplementation significantly improved carotid artery stiffness. The findings mark the longest clinical evidence that beetroot nitrate can bypass the estrogen-eNOS pathway lost at menopause.
AVA-291 Female Testosterone Shows 1,000-Fold Lower Breast Cell Proliferation at AACR 2026
Zero FDA-approved testosterone products exist for women. Aviva Bio's AVA-291 uses deuterium substitution to reduce breast cancer cell proliferation potential by approximately 1,000-fold compared to standard testosterone. Data presented at AACR Annual Meeting, April 2026.
Sourdough Fermentation Lifts Akkermansia and Bifidobacterium in the Gut
Same flour, same oven, different outcome. Research in Frontiers in Microbiology found that sourdough-enriched bread significantly increased Akkermansia and Bifidobacterium populations compared to yeast-leavened bread, while also lowering blood glucose response and LDL cholesterol.
1.2g/kg Protein Restores Muscle Composition in 126 Women Aged 60-75 Over 12 Weeks
A single-blind RCT published in Frontiers in Nutrition found that 1.2g/kg/day protein for 12 weeks significantly improved MRI-measured thigh and calf muscle cross-sectional area in older women with sarcopenia, alongside 2.3x greater fat loss versus the standard 0.8g/kg group.
Pycnogenol Cut Cellulite Visibility by 13.6 Percent in a 60-Woman Three-Month Trial
French maritime pine bark extract Pycnogenol reduced cellulite scores by 12.2 percent at two months and 13.6 percent at three months in a 60-woman Chinese clinical study.
Creatine for Women: The Science Beyond the Gym for Brain and Muscle
Women store 70 to 80 percent less creatine in muscle than men, with especially low levels in the frontal cortex. That gap explains why women may see greater cognitive and metabolic benefits from supplementation, independent of exercise.
Evening Primrose Oil for 12 Weeks, Skin Moisture Up 12.9%, Roughness Down 21.7%
Health and wellness news article.
First Oral Treatment for Female Pattern Hair Loss Enters Phase 2/3 Trial
Veradermics' VDPHL01, an extended-release oral minoxidil tablet, has advanced into Phase 2/3 clinical trials for female pattern hair loss with over 500 women enrolled. Full Phase 2 results expected in 2026.
After 40, Muscle Loss Hits 1-2% Per Year. Protein and Collagen Fight Back.
A Nature npj Aging review establishes that older adults need 35-40g protein per meal to match the anabolic response of younger adults on 20g. And collagen peptides at 5g/day showed +7.7% femoral neck BMD in 12 months.
Rosemary Oil Matches Minoxidil 2% for Hair Growth in 6-Month Trial
A randomized clinical trial in 100 men found no statistically significant difference in hair count between rosemary oil and minoxidil 2% after six months. Active compounds inhibit 5-alpha-reductase at 82 to 95 percent, comparable to finasteride.
PEA 300mg Cut Period Pain by 25% in 2.5 Hours, Trial Shows
A randomized, double-blind, crossover trial found a single 300mg dose of PEA (Levagen+) reduced menstrual pain by ~25% compared to placebo at the 2.5-hour mark, with no difference in adverse events.
Tongkat Ali LJ100 Raises Progesterone and Improves Quality of Life in Menopausal Women
A 12-week double-blind, placebo-controlled trial found LJ100 100mg/day significantly elevated progesterone levels in menopausal women by week 6, with improvements in quality of life, mood, and energy.
Vitamin K2 MK-7 Slows Bone Density Decline in 3-Year Postmenopausal Trial
A 3-year RCT with 142 postmenopausal women with osteopenia showed MK-7 375mcg significantly improved lumbar spine bone mineral density. Results on D3 and calcium co-administration plus skin elasticity potential.
12-Week Beetroot Extract Supplementation Improves Muscle Quality and Neuromuscular Speed in Postmenopausal Women
A randomized clinical trial in 20 postmenopausal women aged 60-85 found that 548mg daily nitrate from beetroot extract significantly improved morphological muscle quality and rate of force development over 12 weeks.
Oxidized Keratin Reduces Hair Loss by 43% in Women 45-60, Skin Benefits Included
A 60-day randomized, double-blind trial in 65 women aged 45-60 found KeraGEN-IV reduced hair loss by 43.1%, improved hair cortex birefringence by 17.6%, increased skin elasticity by 10%, and cut TEWL by 12.5%.
Low Selenium, Hair Loss, and the Thyroid Link
A study comparing 100 women with hair loss against 100 age-matched healthy controls found significantly lower blood selenium levels in the hair loss group. Selenium is essential for thyroid hormone metabolism, and hypothyroidism is a well-established cause of hair loss.
MSM 12-Week Trial: Knee Pain Scores Dropped Significantly
A randomized double-blind trial of 88 adults found MSM 2,000mg daily for 12 weeks significantly reduced knee pain scores (p=0.046) and raised a cartilage synthesis biomarker at week 8.
Iron-Deficiency Hair Loss, Starting Supplementation Within 6 Months Improves Prognosis
Patients who began iron supplementation within 6 months of hair loss onset showed significantly better recovery outcomes. The optimal ferritin target for hair health is 70ng/mL or above, and bisglycinate offers better absorption with fewer GI side effects.
60% of Women with Hair Loss Had Low Ferritin, Researchers Propose 60ng/mL Threshold
A dermatology study found that 60% of women experiencing hair loss had ferritin below 30-40ng/mL. Researchers propose raising the hair-health ferritin target to 60ng/mL with hemoglobin above 13g/dL.
Collagen Supplements Effective for Postmenopausal Women and UV-Damaged Skin
An umbrella review analyzing 113 randomized controlled trials with approximately 8,000 participants found that collagen supplements show significant effects in postmenopausal women and UV-damaged skin, differing from general wrinkle-reduction expectations.
Up to 40% of GLP-1 Weight Loss Comes From Muscle, Nutrition Strategy Is Key
During GLP-1 receptor agonist use, 15~40% of total weight lost can come from muscle. Based on joint recommendations from ACLM, ASN, OMA, and The Obesity Society, here is the nutrition and exercise strategy to preserve lean mass.
Preventing Muscle Loss, Why Protein Alone Is Not Enough
HMB at 3g/day significantly improved grip strength. Vitamin D helps only when correcting deficiency. Leucine, creatine, omega-3, and the limits of supplementation strategy for sarcopenia.
KeraGEN-IV Keratin Supplement Reduces Hair Loss by 43% in 60 Days
A KeraGEN-IV keratin supplement trial involving 65 women aged 45-60 showed 43.1% reduction in hair loss and over 10% increase in skin elasticity within 60 days.
Ingestible Beauty Supplements Grow 17.3% Year-Over-Year
The nutricosmetics market grew 17.3%, with personalized nutrition and microbiome-based beauty emerging as key drivers. Recent clinical data on collagen, resveratrol, and hyaluronic acid adds substance to the trend.
Intermittent Fasting and Female Hormones, Rodent Studies and Human Data Tell Different Stories
Human trials show no effect on estrogen, gonadotropins, or prolactin. Androgen markers decreased, especially in women with PCOS. Early time-restricted eating is the key variable.
Probiotics, Why You Need to Check the Strain Name
Lactobacillus rhamnosus GG and Lactobacillus acidophilus share a genus but produce different outcomes. The latest clinical evidence for strain-specific and disease-specific effects.
Metabolic Flexibility: The Fuel-Switching Ability You Gradually Lose With Age
Mark Mattson published his Cyclic Metabolic Switching theory in Nature Metabolism 2025. Four weeks of time-restricted feeding reversed insulin-related metabolic deficits. Combining ketogenic eating with TRF shows additional benefits.
Menopause Supplements Are Growing Into a Real Science
The women's health supplement market is projected to grow from $57.4 billion in 2024 to $77.4 billion by 2030. D3 plus K2, magnesium glycinate, NAD+ precursors, and urolithin A are the ingredients leading the menopause segment.
22% of U.S. Households Use GLP-1 Drugs. Probiotics Are Filling the Gaps.
With 22% of American households on GLP-1 medications, Expo West 2026 showcased a new category of complementary products. Kerry BC30 reduced GI side effects in a 253-person trial, Saanroo Trpti offers a natural appetite pathway via OEA, and delivery formats are evolving fast.